Form 4: LeonaBio Executive Acquires Stock Options

Javier San Martin, Chief Medical Officer of LeonaBio, Inc., has acquired 350,000 stock options with an exercise price of $9.54.

Summary

• Javier San Martin, Chief Medical Officer at LeonaBio, Inc., was granted 350,000 stock options on April 9, 2026.
• These options have an exercise price of $9.54 per share and an expiration date of April 8, 2036.
• The options are subject to a 48-month vesting schedule, vesting monthly, contingent on continued employment as a Service Provider.
• The filing indicates no prior transactions or amendments to report for this individual.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard executive compensation event without immediate financial performance indicators or strategic shifts.

Positives

• Grant of significant stock options to a key executive (Chief Medical Officer) suggests alignment of executive interests with shareholder value.
• The long expiration date (April 8, 2036) provides a substantial incentive period for the executive.
• The vesting schedule over 48 months encourages long-term commitment to the company.

Negatives

• The filing does not provide details on the rationale behind the option grant or the company's current financial performance, which would contextualize the value of these options.

Risks

• The value of the stock options is directly tied to the future performance of LeonaBio, Inc.'s stock price. A decline in stock price would diminish the value of these options.
• Vesting is contingent on continued employment, meaning the executive could forfeit unvested options if employment ceases.
• The exercise price of $9.54 indicates an expectation of stock price appreciation beyond this level for the options to be profitable.

Future Outlook

The future outlook for the stock options is dependent on the company's stock performance and the executive's continued employment, with vesting occurring over 48 months.

Industry Context

StockSavvy.ai notes that the issuance of stock options to key executives is a common practice in the biotechnology sector to attract and retain talent and align incentives with long-term company growth and value creation.

Stakeholder Impact

• Shareholders: The grant of options can dilute existing share ownership upon exercise, but also aligns executive incentives with increasing shareholder value.
• Employees: May indicate a positive outlook for the company if executive compensation is tied to growth, potentially influencing morale.
• Management: Directly benefits from the potential appreciation of LeonaBio's stock price.

Next Steps

• The executive will vest in the stock options monthly over 48 months, provided they remain employed.
• The executive may exercise the vested options at any time between vesting and the expiration date of April 8, 2036.

Key Dates

Keywords

stock options, executive compensation, LeonaBio, LONA, Form 4, beneficial ownership, securities, equity incentive plan, Javier San Martin